Standout Papers

LBA1 Durvalumab in combination with chemoradiotherapy for patients with unresectable stage III NSCLC: Final results from PACIFIC-2 2024 202630
  1. LBA1 Durvalumab in combination with chemoradiotherapy for patients with unresectable stage III NSCLC: Final results from PACIFIC-2 (2024)
    Jeffrey D. Bradley, Shunichi Sugawara et al. ESMO Open

Immediate Impact

1 by Nobel laureates 15 from Science/Nature 65 standout
Sub-graph 1 of 23

Citing Papers

Redox-responsive polymer micelles co-encapsulating immune checkpoint inhibitors and chemotherapeutic agents for glioblastoma therapy
2024 Standout
Multi drug resistance in Colorectal Cancer- approaches to overcome, advancements and future success
2024 Standout
2 intermediate papers

Works of K.H. Lee being referenced

Durvalumab with or without tremelimumab vs platinum-based chemotherapy as first-line treatment for metastatic non-small cell lung cancer: MYSTIC
2018

Author Peers

Author Last Decade Papers Cites
K.H. Lee 268 310 18 50 17 362
Larry Leon 228 254 27 41 14 309
Alexander Golf 181 309 29 61 13 342
Ilze Bāra 220 253 36 36 22 353
Alessandro Dal Maso 193 275 26 93 23 370
Giuseppe Giaccone 155 289 20 27 17 388
Minal Mehta 298 277 9 82 19 367
J.C.-H. Yang 277 260 18 45 12 345
Ligong Nie 263 258 16 61 23 405
Huiping Qiang 185 273 34 33 20 341
Giulia Grizzi 177 255 37 69 24 354

All Works

Loading papers...

Rankless by CCL
2026